A
114.72
0.15 (0.13%)
| Penutupan Terdahulu | 114.57 |
| Buka | 114.70 |
| Jumlah Dagangan | 514,481 |
| Purata Dagangan (3B) | 2,193,386 |
| Modal Pasaran | 6,708,804,096 |
| Harga / Jualan (P/S) | 289.97 |
| Harga / Buku (P/B) | 16.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -211.46% |
| Margin Operasi (TTM) | -847.56% |
| EPS Cair (TTM) | -2.99 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -79.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.76% |
| Nisbah Semasa (MRQ) | 4.93 |
| Aliran Tunai Operasi (OCF TTM) | -114.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.43 M |
| Pulangan Atas Aset (ROA TTM) | -16.69% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Arcellx, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.60 |
|
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 14.50% |
| % Dimiliki oleh Institusi | 102.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2025 | 6,720,803 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 120.00 (Truist Securities, 4.60%) | Pegang |
| Median | 115.00 (0.24%) | |
| Rendah | 105.00 (Needham, -8.47%) | Beli |
| Purata | 114.55 (-0.15%) | |
| Jumlah | 1 Beli, 10 Pegang | |
| Harga Purata @ Panggilan | 109.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 26 Feb 2026 | 115.00 (0.24%) | Pegang | 113.88 |
| Citigroup | 24 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| Evercore ISI Group | 24 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| Leerink Partners | 24 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| Stifel | 24 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| Truist Securities | 24 Feb 2026 | 120.00 (4.60%) | Pegang | 113.75 |
| UBS | 24 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| 07 Jan 2026 | 100.00 (-12.83%) | Beli | 65.01 | |
| Baird | 23 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| HC Wainwright & Co. | 23 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| 04 Feb 2026 | 115.00 (0.24%) | Beli | 69.38 | |
| Wells Fargo | 23 Feb 2026 | 115.00 (0.24%) | Pegang | 113.75 |
| Needham | 05 Feb 2026 | 105.00 (-8.47%) | Beli | 66.94 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |